Study details
Enrolling now
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
David Wilson
NCT IDNCT05374278ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
102
Study length
about 5.6 years
Ages
40–75
Locations
1 site in CA
What this study is about
Researchers are testing a new imaging agent, called [18F]RP-115, to see if it can help detect early changes in the brains of people with Alzheimer's disease or frontotemporal dementia. The trial will use PET/MRI or PET/CT scans.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take [18F]RP-115 PET/MRI or PET/CT and MRI
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Neurology